Every person deserves the opportunity to receive the treatment that is best matched to their unique cancer. CureMatch is helping transform cancer care by giving physicians advanced precision medicine tools that identify personalized treatment options based on the genetic makeup of each patient’s tumor.
With your support, we can provide more life-changing reports for patients with complex cancers, expand access to families who need our help most, generate the clinical evidence needed to make this technology more widely available, and accelerate research that will benefit future generations. Every report represents another patient with renewed hope, another physician empowered with better information, and another step toward making personalized cancer treatment the standard of care.
SHARE:
Cancer is never just a diagnosis. Every person’s cancer is different, with its own unique biological makeup, which means the treatment that works for one patient may not work for another. At CureMatch, we’ve met families searching for hope when standard treatments have stopped working – a daughter looking for more options for her father, a young mother determined to watch her child grow up, and physicians who refuse to accept that there is “nothing more that can be done.” Behind every medical decision is a person, a family, and a future worth fighting for.
CureMatch uses advanced technology to help doctors find the treatments that are most likely to work for each individual patient. By analyzing the unique genetic characteristics of a person’s tumor, the platform identifies and ranks personalized treatment options – including combinations of medicines and clinical trials – that best match that patient’s cancer. Rather than relying on trial and error, CureMatch gives physicians evidence-based insights to make more informed decisions. While no technology can guarantee a cure, it can provide greater confidence, more personalized care, and renewed hope. Every cancer has its own story. Every patient deserves the best possible chance to write the next chapter.
Every day, we work with physicians and families facing some of the most difficult cancer cases—patients who have exhausted standard treatment options or whose cancers are simply too complex for conventional approaches. Whenever possible, we go beyond our standard services to help. For years, we have provided our reports for children with cancer at no cost and have offered reduced pricing for patients with especially urgent or challenging cases because we believe that access to personalized cancer care should never depend solely on the ability to pay. As demand for precision medicine continues to grow, however, sustaining this level of support has become increasingly difficult. Additional funding would allow us to continue helping these patients while expanding our team of scientific experts to provide deeper genetic analysis, more comprehensive treatment recommendations, and specialized support for physicians caring for the most complex cases.
Support for our work would also help us advance the future of precision oncology. It would enable us to conduct research that improves cancer care, generate the clinical evidence needed to expand insurance coverage so more patients can access our technology, and strengthen collaborations with hospitals, researchers, and pharmaceutical companies developing the next generation of cancer therapies. By growing our scientific, clinical, and business development teams, we can bring these life-saving tools to more physicians and more patients around the world. Our goal is simple: to ensure that every person facing cancer has access to the most informed, personalized treatment options possible – and, with them, a greater chance for more time, better outcomes, and renewed hope.
To achieve these goals, we are seeking to raise $580,000 to support one year of funding for three critical leadership positions: our Chief Scientific Officer, Vice President of Engineering, and Director of Clinical Science. These experts are the driving force behind our platform – advancing the science, refining the technology, and ensuring that every clinical report is grounded in the latest evidence and delivered with the highest level of accuracy. Investing in this team will enable us to expand access to personalized cancer treatment, accelerate research collaborations, improve reimbursement efforts, and ultimately help more patients and physicians navigate cancer with confidence and hope.
By expanding our reach and helping more cancer patients, we can build the clinical evidence and momentum needed to attract additional investment and accelerate the growth of CureMatch. Every patient served, every physician supported, and every success story strengthens our ability to bring personalized cancer treatment to more people around the world.
Funding will also allow us to expand education and awareness for patients, patient advocates, physicians, healthcare providers, insurers, and nonprofit organizations. Many patients are still unaware that comprehensive genomic testing and precision medicine may open the door to more personalized treatment options. By increasing awareness of these tools and the clinical decision support that CureMatch provides, we can empower more patients and their care teams to make informed treatment decisions, helping extend lives, improve outcomes, and bring the promise of precision oncology to everyone who could benefit from it.
If CureMatch were unable to continue its work, patients and physicians would lose access to a powerful tool that helps personalize cancer treatment based on the unique biology of each person’s tumor. Too many patients would continue receiving treatments that are less likely to work, while missing opportunities to explore therapies and clinical trials that may offer greater hope. For individuals facing advanced or treatment-resistant cancers, where every decision matters, the loss of this technology could mean fewer options, more unnecessary side effects, and precious time lost.
Supporting CureMatch is about more than sustaining a company – it’s about ensuring that life-changing innovation reaches the people whose lives depend on it. Your investment helps bridge the gap between breakthrough science and everyday patient care, allowing more physicians to make informed treatment decisions and more families to benefit from precision medicine. Together, we can accelerate the future of personalized cancer care, expand access to innovative technologies, and help ensure that every patient has the best possible chance to live longer, live better, and face cancer with renewed hope.
Chief Meidcal Officer & Co-Founder
Dr. Kurzrock is a world leader in precision medicine and immunotherapy. As a medical oncologist/researcher, she is recognized as one of the most important voices in precision medicine and one of the most highly cited scientists globally. Dr. Kurzrock is known for founding and chairing the largest Phase 1 clinical trials department in the world while at the MD Anderson Cancer Center. More recently, at the University of California, Dr. Kurzrock founded and led the Rare Tumor Clinic and the Center for Personalized Cancer Therapy.
Dr. Kurzrock has brought oversight to >500 clinical trials, with many agents yielding FDA approvals. She has authored >900 peer-reviewed paper with an exception Hirsch index (h-index) score of 136 (>77,000 citations). Her strong record of competitive funding is comprised of ~$125 million in lifetime funding. She has four children, two Basenjis (dogs) and is married to Philip Cohen, MD, who is a dermatologist.
Co-founder and Chief Executive Officer
Navid is a long-time entrepreneur in the AI space with an emphasis on the convergence of AI and the life sciences, increasingly called Wellness Science.
Navid serves on the Board of Tech San Diego, helping build the thriving ecosystem in San Diego. He is on the Board of CureMetrix, CureMatch, DynamAI, and AlphaTrAI. Navid is a sought-after panelist, judge, speaker, and moderator on the topics of venture capital, artificial intelligence, healthcare, and entrepreneurship at various forums such as UCSD, USD, SDSU, CyberHive, MIT Forum, RSNA, U.S. News STEM Conference, and CONNECT. Navid holds a BA from UC San Diego, and a JD/MBA from the University of San Diego.
Chief Scientific Officer
Ally is a proven executive leader who has dedicated nearly two decades of industry experience to solving challenging problems in precision medicine, health-tech, and pharmaceutical fields to improve human health with molecular-level personalization. She is a visionary innovator with a track record of translating complex data into actionable insights delivered as scalable AI products by integrating analytics with systems biology and knowledge management techniques.
Ally developed unique methodology for automated pathway analysis personalizing nutraceuticals at scale. Previously, at Human Longevity, Inc. (HLI), co-founded by Craig Venter, Ally spearheaded the Comprehensive Cancer Program creating novel analytics for clinical decision support. At tumor boards, she provided mechanistic rationale for drug and trial prioritization. Ally’s experience also includes working with top pharma at a systems biology startup acquired by Thomson Reuters, researching cancer at SBP, working at a CLIA lab acquired by Quest, and focusing on clinical genomics of brain tumors in her graduate training at the UCLA Ph.D. program in Human Genetics where she also earned her M.S. degree. Ally received her B.S. in Biochemistry and Cell Biology from UCSD. She is a published author and an inventor on several patents.
